/KAPA

KAPA Stock - Kairos Pharma, Ltd.

Q: What is the analyst price target for KAPA?

Analyst price target information is not currently available for KAPA.

Q: What is KAPA's market cap?

Market capitalization information is not currently available for KAPA.

Healthcare|Biotechnology|AMEX

$0.86+10.76%

+$0.08 (+10.76%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.94

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KAPA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.20

52W High$3.25

52W Low$0.40

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-160,000	$-160,000	$-160,000	$-98,000	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-2,343,000	$-1,714,000	$-571,000	$-1,943,000	$-1,045,941
Net Income	$-2,603,000	$-1,812,000	$-1,050,000	$-2,145,000	$-1,051,353
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.23	$-0.17	$-0.10	$-0.17	$-0.09

Company Overview

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Visit Website

Earnings History & Surprises

KAPA

Beat Rate

20%

Last 5 quarters

Avg Surprise

-101.4%

EPS vs Estimate

Beats / Misses

1/4

Last 12 quarters

Latest EPS

$-0.07

Q4 2025

EPS Surprise History

Q4 23

No data

Q1 24

No data

Q2 24

No data

Q4 24

-400.0%

$-0.10vs$-0.02

Q1 25

-43.8%

$-0.09vs$-0.06

Q2 25

-60.0%

$-0.08vs$-0.05

Q3 25

-33.3%

$-0.08vs$-0.06

Q4 25

+30.0%

$-0.07vs$-0.10

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 21, 2026	$-0.12	—	—	—
Q4 2025	Nov 14, 2025	$-0.10	$-0.07	+30.0%	✓ BEAT
Q3 2025	Aug 12, 2025	$-0.06	$-0.08	-33.3%	✗ MISS
Q2 2025	Apr 15, 2025	$-0.05	$-0.08	-60.0%	✗ MISS
Q1 2025	Feb 26, 2025	$-0.06	$-0.09	-43.8%	✗ MISS
Q4 2024	Nov 14, 2024	$-0.02	$-0.10	-400.0%	✗ MISS
Q2 2024	Jun 30, 2024	—	$-0.02	—	—
Q1 2024	Mar 31, 2024	—	$-0.03	—	—
Q4 2023	Dec 31, 2023	—	$-0.11	—	—
Q3 2023	Sep 30, 2023	—	$-0.03	—	—
Q2 2023	Jun 30, 2023	—	$-0.02	—	—
Q1 2023	Mar 31, 2023	—	$-0.01	—	—
Q4 2022	Dec 31, 2022	—	$-0.02	—	—
Q3 2022	Sep 30, 2022	—	$-0.02	—	—
Q2 2022	Jun 30, 2022	—	$-0.04	—	—
Q1 2022	Mar 31, 2022	—	$-0.02	—	—